Related Experiment Videos
Recombinant hepatitis B triple antigen vaccine: Hepacare
Jane N Zuckerman1, Arie J Zuckerman
1Academic Centre for Travel Medicine and Vaccines, Royal Free and University College Medical School, University College of London, UK. j.zuckerman@rfc.ucl.ac.uk
Expert Review of Vaccines
|August 7, 2003
Summary
A new triple-antigen hepatitis B vaccine, Hepacare, effectively addresses non-responsiveness and hypo-responsiveness in individuals who do not adequately respond to current single-antigen hepatitis B vaccines.
Area of Science:
- Hepatitis B research
- Vaccinology
- Immunology
Background:
- Hepatitis B virus infection is a global public health concern.
- Current hepatitis B vaccines are widely used but fail to elicit protective antibody responses in 5-10% of healthy individuals.
- Non-responsiveness and hypo-responsiveness to existing vaccines pose a challenge for achieving herd immunity.
Purpose of the Study:
- To evaluate the efficacy of a novel triple-antigen hepatitis B vaccine (Hepacare) in overcoming non-responsiveness and hypo-responsiveness.
- To assess the potential of Hepacare for individuals requiring rapid protection against hepatitis B.
Main Methods:
- Development of a novel triple-antigen vaccine incorporating pre-S1 and -S2 hepatitis B surface antigen components.
- Administration of the triple-antigen vaccine to individuals identified as non-responders or hypo-responders to single-antigen vaccines.
Main Results:
- The triple-antigen vaccine demonstrated effectiveness in a significant number of individuals who were previously non-responsive or hypo-responsive.
- Hepacare successfully induced protective immune responses in a notable proportion of the target population.
Conclusions:
- The novel triple-antigen hepatitis B vaccine (Hepacare) offers a promising solution for individuals with suboptimal responses to current vaccines.
- This vaccine has the potential to improve hepatitis B prevention strategies, particularly for non-responders and those needing rapid protection.